Yaupon Therapeutics is a privately-held specialty pharmaceutical company that develops small molecule pharmaceuticals licensed from under-served academic laboratories. The Company’s lead product candidate, Clearazide™, a proprietary topical formulation of nitrogen mustard (NM), is being evaluated in a pivotal Phase II/III trial under a Special Protocol Assessment (SPA) with the FDA for the treatment of early-stage cutaneous T-cell lymphoma – mycosis fungoides (CTCL-MF). The FDA has granted Clearazide™ fast-track designation and orphan drug status.